EQUITY ALERT: The M&A Class Action Firm Is Investigating the Merger -- UTZ, SAFT, PASG and FNWD - IS IT A FAIR DEAL FOR YOU?

Monteverde & Associates said it is investigating the proposed sales of Utz Brands for $14.25 per share in cash and Safety Insurance Group for $105.00 per share in cash, as well as Passage Bio’s merger with Remix Therapeutics and Finward Bancorp’s proposed sale for 1.35 First Financial shares per Finward share. The firm’s advertisement asks shareholders to inquire about the fairness of the transactions; it reports no legal finding or outcome.

Analysis

This is an attorney-advertising solicitation, not evidence that a complaint has been filed, that a transaction is impaired, or that any deal is unfair. Its immediate information content is therefore low; the key market mechanism is a possible increase in closing-delay risk only if an actual suit seeks meaningful relief or a court imposes a procedural hold. Do not treat the solicitation itself as a change to deal value.

Over the next days, any reaction should be assessed through each target’s deal spread—not the headline. For Utz Brands (UTZ) and Safety Insurance Group (SAFT), the stated consideration is cash, so the relevant exposures are closing timing, financing/approval conditions, and downside to unaffected value if a deal breaks. For Finward Bancorp (FNWD), consideration is 1.35 shares of First Financial Bancorp (FFBC) per share; its implied value moves with FFBC, making a fixed-cash interpretation inappropriate. Passage Bio (PASG) has no consideration or other merger terms in this release, so there is no basis here to estimate arb value.

Over 1–3 months, monitor court filings, proxy disclosures, shareholder votes, and regulatory milestones. A filed action alone may have little effect; an injunction request, adverse ruling, or delayed vote could widen spreads. The contrarian point is that the solicitation may invite investors to overread routine deal-related legal marketing as substantive transaction risk. No trade is supported without current prices, deal documents, closing conditions, and—especially for PASG—the merger consideration.

Key Decisions for Investors

• No directional position based solely on this release. Verify whether any complaint has actually been filed, its requested relief, and whether a court or the companies disclose a resulting delay.
• Track UTZ and SAFT against their respective cash consideration and estimate deal-break downside only after reviewing unaffected prices, closing conditions, and expected timing; avoid paying for a spread that does not compensate for break risk.
• For FNWD, analyze deal value as 1.35 FFBC shares per FNWD share. A potential market-neutral hedge would pair long FNWD with short 1.35 FFBC shares per FNWD share, but only after checking current spread, borrow, deal terms, and termination protections.
• Keep PASG on watch rather than trading the merger headline: obtain the merger agreement and consideration terms first. Reassess all names if a court filing seeks an injunction, a ruling delays closing, or disclosed votes/regulatory approvals weaken.